Table 1.
TOTAL | CR | DR | LR | |
---|---|---|---|---|
(n = 199) | (n = 120) | (n = 36) | (n = 43) | |
Age, yo ± SD | 62.5 ± 10.2 | 61.3 ± 8.9 | 64.0 ± 10.2 | 64.7 ± 12.7 |
Gender, n (%) | ||||
Male | 142(71.4) | 85(70.8) | 26(72.2) | 31(72.1) |
Female | 57(28.6) | 35(29.2) | 10(27.8) | 12(27.9) |
Tumor location, n (%) | ||||
Rhinopharynx | 7(3.5) | 5(4.2) | 1(2.8)* | 1(2.3)* |
Oropharynx | 124(62.3) | 70(58.3) | 26(72.2)* | 28(65.1)* |
Hypopharynx | 24(12.1) | 14(11.7) | 5(13.9)* | 5(11.6)* |
Larynx | 31(15.6) | 26(21.7) | 3(8.3)* | 2(4.7)* |
Oral cavity | 13(6.5) | 5(4.2) | 1(2.8)* | 7(16.3)* |
AJCC stage, n (%) | ||||
I | 5(2.5) | 5(4.2) | 0* | 0* |
II | 16(8.0) | 14(11.7) | 0* | 2(4.6)* |
III | 40(20.1) | 28(23.3) | 5(13.9)* | 7(16.3)* |
IV | 138(69.3) | 73(60.8) | 31(86.1)* | 34(79.1)* |
RT Duration, (days ± SD) | 54.8 ± 9.1 | 53.4 ± 9.4 | 56.7 ± 7.5 | 57.3 ± 8.5 |
RT Dose, (Gy ± SD) | 70.0 ± 1.1 | 70.0 ± 0.5 | 70.3 ± 1.2 | 69.9 ± 1.8 |
Treatment, n (%) | ||||
CRT | 137(68.9) | 85(20.8) | 26(72.2) | 26 (60.5) |
Single RT | 56(28.1) | 31(25.8) | 8(22.2) | 17(39.5) |
CR, Complete response; DR, Distant relapse; LR, Local relapse; SD, Standard deviation; CRT, Chemo-radiotherapy;
Significantly different fromCR.